Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of 14C-TERN-701 in Healthy Adult Males
NCT07839000Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2026
- Primary completion
- Apr 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TERN-701, sponsored by Merck & Co. Primary endpoints: Pharmacokinetic Parameters of TERN-701 and [14C]-Radiolabel in Plasma and Whole Blood up to 408 hours, Excretion of [14C]-Radiolabel in Urine and Feces up to 408 hours and 1 more. Started Feb 2026; status: completed.
02
Drugs
TERN-701
Beyond the preview
Go deeper on NCT07839000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07839000.